交易 BioNTech BNTX

BioNTech實時圖表

金融工具基礎知識

Weekly Search
Weekly
Daily
日期 關閉 更改 更改(%): 開倉

最新新聞

Frances Wang 2025 Mar 30, 16:00

哈雷戴維森第四季度銷售暴跌:哈雷戴維森的營收下降60%

So Ze Dong 2025 Mar 25, 16:00

S&P500指數三連漲!GameStop宣布投資比特幣股價狂飆

Christine Voong 2025 Mar 21, 07:30

黃金價格走勢受美元走勢影響回落,仍穩守 3,000 美元關口

Christine Voong 2025 Mar 21, 04:40

美元指數走強至 103.81 點,美聯儲維持利率不變,市場關注貿易關稅與美元匯率走勢

Christine Voong 2025 Mar 20, 08:20

黃金價格走勢創歷史新高!現貨金觸及 3,057 美元,美聯儲降息預期與美元走勢疲弱支撐漲勢

Christine Voong 2025 Mar 20, 07:25

比特幣價格走勢上揚!美聯儲維持降息預測,加密貨幣市場風險偏好回暖

Christine Voong 2025 Mar 19, 08:00

國際原油價格走勢承壓:美國原油庫存激增,美俄停火協議影響供應預期

Christine Voong 2025 Mar 19, 07:25

國際黃金價格創歷史新高!避險需求推升,美聯儲決策影響黃金價格走勢

聯絡方式

點差

1.1057

點差(%)

1.2461 %

槓桿

1:10

隔夜利息(買入)

-0.0597 %

隔夜利息(賣出)

-0.0292 %

貨幣

USD

交易時間

市場開放

星期二

13:31 - 19:59

星期一

13:31-19:59

星期三

13:31-19:59

星期四

13:31-19:59

星期五

13:31-19:59

分析與統計

開倉

---

上一次平倉

---

52 週高點/低點

--- – ---

市值

22785214464

流通股份

239971008

收益日期(下一個)

0000-00-00

現金殖利率 

2022-06-17

除息日

2022-06-02

遠期年股息率

0

遠期年現金殖利率

0

每股盈餘

-3.01

了解有關此金融工具的詳細資訊

BioNTech BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors. It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

相關工具

資產
出售
購買
更改(%):
查看所有金融工具
Trustpilot